Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipiodol Embolization in Symptomatic Digital Osteoarthritis
NCT06611007Phase 2Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ethiodized oil in osteoarthritis (OA), sponsored by CHU Grenoble Alpes. Primary endpoint: Number and Frequency of Embolisation-Related Adverse Events at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
ethiodized oil
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06611007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611007.